New medical treatments in Cushing disease;Nouvelles thérapeutiques médicales dans la maladie de Cushing

Annales d'Endocrinologie

Volumn 68, Issue SUPPL. 1, 2007, Pages 18-20

  Bricaire, L ^a   Brue, T ^b  

^a HÔPITAL SAINT ANTOINE   (France)

^b TIMONE HOSPITAL   (France)

Author keywords

Dopaminergic agonists and Cushing disease; Interferon gamma and Cushing disease; Octreotid and Cushing disease; SOM230; Thiazolinedinedione and Cushing disease

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CABERGOLINE; CORTICOTROPIN; DOPAMINE 2 RECEPTOR; GAMMA INTERFERON; GLITAZONE DERIVATIVE; KETOCONAZOLE; OCTREOTIDE; PASIREOTIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; RETINOIC ACID; RETINOID; ROSIGLITAZONE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 5;

ARTICLE; CUSHING DISEASE; DRUG EFFECT; DRUG RECEPTOR BINDING; EXPERIMENTAL DOG; HUMAN; HYDROCORTISONE RELEASE; HYPOPHYSIS ADENOMA; NONHUMAN; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR CELL;

HUMANS; INTERFERON-GAMMA; PITUITARY ACTH HYPERSECRETION; RECEPTORS, DOPAMINE; RETINOIDS; SOMATOSTATIN; THIAZOLIDINEDIONES;

EID: 35348959994     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0003-4266(07)80005-9     Document Type: Article

References (12)

1. Ambrosi B., Dall'Asta C., Cannavo S., et al. Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease. Eur J Endocrinol 151 (2004) 173-178
2. Batista D., Zhang X., Gejman R., et al. The effects of SOM230 on cell-proliferation and adrenocorticotropin secretion in human corticotrph pituitary adenomas. J Clin Endocrinol Metab 91 (2006) 4482-4488
3. Castillo V., Giacomini D., Paez-Pereda M., et al. Retinoïc Acid as a novel medical therapy for Cushing's disease in dogs. Endocrinology 147 (2006) 4438-4444
4. Giraldi F., Scaroni C., Arvat E., et al. Effects of protracted treatment with rosiglitazone, a PPAR-gamma agonist, in patients with Cushing's disease. Clin Endocrinol 64 (2006) 219-224
5. Heaney A., Fernando M., Yong W., and Melmed S. Functionnal PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med, 8 (2002) 1281-1287
6. Hofland L., van der Hoek J., Feelders R., et al. The multi-ligand somatostatin analogue SOM 230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 152 (2005) 645-654
7. Lamberts S., de Herder W., Krenning E., and Reubi J. A role of somatostatin analogs in the differential diagnosis and treatment of Cushing's syndrome. J Clin Endocrinol Metab 78 (1994) 17-19
8. Paez-Pereda M., Kovalovsky D., Hopfner U., et al. Retinoic acid prevents expérimental Cushing Syndrome. J Clin Invest 108 (2001) 1123-1131
9. Pivonello R., Ferone D., de Herder W., et al. Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 89 (2004) 2452-2462
10. Stalla G., Brockmeier S., Renner U., et al. Octreotide exerts different effects in vivo and in vitro in Cushing's disease. Eur J Endocrinol 130 (1994) 125-131
11. Suri D., and Weiss R. Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease. J Clin Endocrinol Metab 90 (2005) 1340-1346
12. Weckbecker G., Briner U., Lewis I., and Bruns C. SOM 230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor receptor binding and a unique antisecretory profile. Eur J Endocrinol 143 (2002) 4123-4130